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The sequence-selective binding of pentamidine, an antimicrobial romatic diamidine, has been investigated by footprinting studies on two different 
DNA fragments using DNase I, micrococcal nuclease and hydroxyl radical as probes. Each probe reveals drug-induced protection from cleavage 
in AT-rich regions. The best binding sites consist of at least 5 consecutive AT base pairs. Three or less AT pairs do not constitute a pentamidine 
binding site. 
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1. INTRODUCTION 
Pentamidine is an antimicrobial gent useful for the 
treatment ofvarious protozoal infections [1]. Attention 
has recently been focused on this compound as it is ef- 
fective in treating Pneumocystic carinii pneumonia,  
recurring opportunistic infection in patients with 
AIDS, proving fatal in about 20°7o f cases in each cycle 
of infection [2]. Although the mode of action of pen- 
tamidine is unknown, several lines of evidence suggest 
that DNA may be its molecular target [1]. It is a mem- 
ber of the class of aromatic diamidines, several of 
which have been shown to bind to DNA. Both circular 
dichroism and melting point studies have shown that 
pentamidine forms complexes with AT-rich DNAs 
[3,4]. Recent molecular mechanics modelling studies, 
based on the crystal structure of pentamidine ise- 
thionate [5], have suggested that the drug binds to the 
DNA minor groove spanning 4 base pairs with the 
charged amidinium groups forming hydrogen bonds to 
02 of thymine or N3 of adenine [6]. 
In this study we examine the sequence-selective 
binding of pentamidine to two DNA fragments using a 
variety of footprinting techniques. 
2. MATERIALS AND METHODS 
2.1. Drugs 
Pentamidine isothionate was purchased from Sigma and stored as 
a 10 mM solution in 10 mM Tris-HC1, pH 8.0, containing 10 mM 
NaCl. 
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2.2. DNA fragments 
The 160 base pair tyrT DNA fragment (Fig. 2) was isolated and 
labelled at the 3' -end of either the EcoRI site with [oe-3zP]dATP (bot- 
tom strand) or the Aval site with [oe-3zP]dCTP (top strand) using 
reverse transcriptase [7]. The 270 base pair EcoRI-HindlII kineto- 
plast DNA fragment [8] (Fig. 2) was isolated from plasmid pK201/ 
CAT (a gift from Dr T. Tullius) and labelled at the EcoRI end with 
[a-32p]dATP using reverse transcriptase. 
2.3. Footprinting 
Footprinting reactions were performed as previously described us- 
ing DNase I [7], micrococcal nuclease (MNase) [9] and hydroxyl 
radicals [10]. The products of the reactions were resolved on 6-807o 
polyacrylamide gels containing 8 M urea. Gels were fixed in 10o70 
acetic acid before drying under vacuum at 80°C and subjecting to 
autoradiography at - 70°C using an intensifying screen. Bands in the 
autoradiographs of DNase I and hydroxyl radical digests were as- 
signed by comparison with Maxam-Gilbert dimetylsulphate-piperi- 
dine markers specific for guanine. Since MNase cuts the O5 ' -P  
bond, in contrast to the O3'-bond which is cleaved by DNase I, the 
bands do not comigrate with the G-marker lanes. Bands in MNase 
digests were therefore assigned using the observation that MNase on- 
ly cuts pA and pT bonds [11] and by comparison with previous work 
[9]. 
3. RESULTS 
3.1. tyrT DNA 
Fig. 1 presents the results of DNase I digestion of 
tyrT DNA in the presence and absence of pentamidine. 
Drug concentrations of 5/zM and above have altered 
the nuclease digestion pattern, confirming that pen- 
tamidine possesses ome sequence selectivity. Even at 
100/~M many regions are still cleaved by the enzyme, 
suggesting that the drug does not bind to certain se- 
quences. The clearest regions of protection, visible with 
5 #M drug on both DNA strands, can be seen around 
positions 28, 45 and 130. Other sites around positions 
65, 80 and 110 are evident with concentrations of
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Fig. 1. DNase I and hydroxyl radical (Fe-EDTA) footprinting of pentamidine on tyrT DNA. For DNase I cleavage ach pair of lanes corresponds 
to digestion by the enzyme for 1 and 5 min. The sequence numbering and strand designation correspond to the sequence shown in Fig. 2. The 
track labelled 'G' is a Maxam-Gilbert dimethylsulphate-piperidine marker specific for guanine. The pentamidine concentrations were: (A) control 
0#M; (B) 1 #M; (C) 5 #M; (D) 25 #M; (E) 100#M. 
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Fig. 2. Sequences of the tyrT and kinetoplast DNA fragments and the protections from DNase I and hydroxyl radical cleavage afforded by 
pentamidine. For kinetoplast DNA only the strand bearing the radioactive label is shown. The radiolabelled bases are unde lined. Boxes indicate 
regions protected from hydroxyl radical attack, the filled boxes show the stronger binding sites. The lines indicate protection from DNase I, the 
broken lines correspond to the weaker sites. For kinetoplast DNA binding sites were resolved between 230 and 130. 
25/zM and above. The protected regions are summaris- 
ed in Fig. 2 from which it can be seen that each of the 
footprints is located in an AT-rich region. It is worth 
noting that no drug-induced enhancements in DNase I 
cleavage are apparent, in contrast o results obtained 
with distamycin [7]. 
DNase I provides a low resolution map of the drug 
binding sites, on account of its size and the non- 
uniform nature of the control cleavage pattern. A 
clearer picture is obtained using hydroxyl radicals as a 
probe. These generate an even ladder of cleavage pro- 
ducts and have previously been used to map drug bin- 
ding sites at high resolution [10,12,13]. Hydroxyl 
radical footprints of pentamidine on tyrT DNA are 
presented in Fig. 1 and reveal attenuated cleavage pat- 
terns in the presence of the drug. This observation is in- 
formative since many sequence selective DNA-binding 
drugs such as actinomycin and nogalamycin do not 
yield hydroxyl radical footprints [14]. The bands show- 
ing the best protection can be seen at positions 
129-131, 50-52 and 30-32 on the top strand and posi- 
tions 27-29, 46-48, 126-128 on the bottom strand. 
These correspond exactly to the regions showing the 
best protection from DNase I attack. At each site the 
blockage is staggered by 2-3 bonds in the 3' -direction, 
as expected for a cleavage agent cutting from the minor 
groove. Other weaker sites of protection are also evi- 
dent on both strands; these correspond to the weaker 
sites of protection seen with DNase I. Both the weak 
and strong cleavage sites are summarised in Fig. 2. In- 
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Fig. 3. Micrococcal nuclease footprinting of pentamidine on the tyrT 
DNA fragment labelled on the bottom strand of the sequence shown 
in Fig. 2. Each pair of lanes corresponds to digestion by the enzyme 
for 1 and 5 min. The drug concentrations (aM) are shown at the top 
of each pair of lanes. 
Fig. 4. DNase I and hydroxyl radical (Fe-EDTA) footprinting of 
pentamidine on the kinetoplast DNA fragment. For DNase I cleavage 
each pair of lanes corresponds to digestion by the enzyme for 1 and 
5 minutes. The numbers correspond tothe sequence shown in Fig. 2. 
The track labelled 'G' is a Maxam-Gilbert dimethylsulphate- 
piperidine marker specific for guanine. The pentamidine concentra- 
tions were: (A) control 0 IzM; (B) 1/zM; (C) 5/~M; (D) 25/tM. 
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spection of Fig. 2 reveals that although all the sites are 
in AT-rich regions those best protected contain runs of 
6 or more AT base pairs whereas the weaker ones all 
consist of 4 AT pairs. Three contiguous AT pairs do 
not appear to constitute a binding site since no protec- 
tion is apparent around position 60 (TAA). 
In order to confirm these observations we have per- 
formed footprinting experiments on the same DNA 
fragment using micrococcal nuclease as a probe. This 
enzyme cuts exclusively at pT and pA bonds and is 
especially useful for investigating ligands which bind to 
AT-rich regions. The results are presented in Fig. 3 and 
reveal that 5/zM pentamidine inhibits MNase attack 
specifically at positions 47 and 126/127, regions which 
correspond to the best sites seen with DNase I and 
hydroxyl radicals. At concentrations of 25/zM and 
above many more protections are evident, so that by 
100/zM few cleavage products remain as would be ex- 
pected for a ligand with broad AT-selectivity. 
3.2. Kinetoplast DNA 
Fig. 4 presents the results of DNase I and hydroxyl 
radical digestion of the kinetoplast DNA fragment in 
the presence and absence of pentamidine. This DNA 
contains runs of adenines paced at 10 base pair inter- 
vals and so adopts an unusual bent structure [15]. As 
a result, the control digestion patterns are uneven 
displaying a phased pattern of bands for both DNase I 
and hydroxyl radicals as previously noted [15]. The 
minima in these cleavage patterns are found at the 
3' -end of each of the blocks of A and T. In the 
presence of pentamidine this phasic cleavage pattern is 
accentuated so that for DNase I weaker cleavage 
products in between the maxima are no longer visible. 
With hydroxyl radicals the troughs in the cleavage pat- 
tern are more pronounced. The protections observed 
with hydroxyl radicals are summarised in Fig. 2 and 
confirm that each is located towards the 3' -end of each 
of the runs of A and T. The results with tyrT DNA sug- 
gested that good pentamidine binding sites consist of 
runs of over 4 AT base pairs; it is therefore not surpris- 
ing that kinetoplast DNA presents many excellent 
binding regions. 
4. DISCUSSION 
The results presented here demonstrate that pen- 
tamidine is an AT-selective DNA binding ligand. The 
best binding sites contain runs of 5 or more AT base 
pairs, though runs of 4 AT pairs are protected from 
cleavage at higher concentrations. Three consecutive 
AT pairs do not constitute a binding site. This is consis- 
tent with previous molecular mechanics tudies which 
revealed a binding site size of 4 base pairs [6]. However, 
the modelling studies suggested that the drug could 
tolerate a single GC pair within the binding site; this is 
not confirmed with the footprinting data with DNase I 
and hydroxyl radicals, though the abolition of MNase 
activity at high concentrations of pentamidine may 
reveal weaker binding to other DNA regions. The drug 
does not appear to distinguish between homopolymeric 
and alternating regions of A and T. In contrast o dista- 
mycin, no enhancements in DNase I activity sites were 
observed suggesting that pentamidine causes few 
changes in DNA structure. The footprinting data 
together with the molecular mechanics calculations sug- 
gest that pentamidine binds in the DNA minor groove 
forming hydrogen bonds between its amidinium groups 
and adenine N3 or thymine 02  bridging 4 or 5 base 
pairs. Selectivity for A or T in the intervening pairs is 
achieved by exclusion of GC as a result of the guanine 
2-amino group, protruding into the minor groove, in- 
terrupting the mainly hydrophobic interaction between 
the drug molecule and the exposed DNA surface. 
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